Financial statements Notes to the financial statements 43 Principal Group companies The following represent the principal subsidiaries and associates of the GlaxoSmithKline Group at 31 December 2013.
Details are given of the principal country of operation, the location of the headquarters, the business sector and the business activities.
The equity share capital of these entities is wholly owned by the Group except where its percentage interest is shown otherwise.
All companies are incorporated in their principal country of operation except where stated.
Europe Location Subsidiary Sector Activity % England Brentford GlaxoSmithKline Holdings Limited Ph, CH h Brentford GlaxoSmithKline Services Unlimited Ph, CH s Brentford GlaxoSmithKline Mercury Limited Ph h Brentford GlaxoSmithKline Finance plc Ph, CH f Brentford GlaxoSmithKline Capital plc Ph, CH f Brentford SmithKline Beecham Limited Ph, CH d e h m p r Brentford Wellcome Limited Ph, CH h Brentford Glaxo Group Limited Ph h Brentford Glaxo Operations UK Limited Ph p Brentford GlaxoSmithKline Export Limited Ph e Brentford GlaxoSmithKline Research & Development Limited Ph d r Brentford GlaxoSmithKline UK Limited Ph m p Brentford Setfirst Limited Ph, CH h Brentford GlaxoSmithKline Trading Services Limited i iv Ph e Brentford ViiV Healthcare Limited Ph h 77 Brentford ViiV Healthcare UK Limited Ph m s 77 Austria Vienna GlaxoSmithKline Pharma GmbH Ph m Belgium Wavre GlaxoSmithKline Pharmaceuticals S. A. Ph m Rixensart GlaxoSmithKline Biologicals S. A. Ph d e m p r Czech Republic Prague GlaxoSmithKline s. r. o. Ph, CH m France Marly le Roi Groupe GlaxoSmithKline S. A. S. Ph h Marly le Roi Laboratoire GlaxoSmithKline S. A. S. Ph m r d Marly le Roi Glaxo Wellcome Production S. A. S. Ph p Marly le Roi GlaxoSmithKline Sante Grand Public S. A. S. CH m Marly le Roi ViiV Healthcare S. A. S. Ph m 77 St. Amand Les Eaux GlaxoSmithKline Biologicals S. A. S. Ph p Germany Buehl GlaxoSmithKline Consumer Healthcare GmbH & Co. KG CH h m s Munich GlaxoSmithKline GmbH & Co. KG Ph d h m s Greece Athens GlaxoSmithKline A. E. B. E Ph, CH m Italy Verona GlaxoSmithKline S. p. A. Ph d m Milan GlaxoSmithKline Consumer Healthcare S. p. A. CH m Netherlands Zeist GlaxoSmithKline B. V. Ph m Poland Poznan GlaxoSmithKline Pharmaceuticals S. A. Ph p Poznan GSK Services Sp.
z o. o. Ph m s Republic of Carrigaline SmithKline Beecham Cork Limited i Ph d p r Ireland Dublin GlaxoSmithKline Consumer Healthcare Ireland Limited i CH m Dublin GlaxoSmithKline Ireland Limited i Ph m Dungarvan Stafford Miller Ireland Limited i CH p Dungarvan GlaxoSmithKline Dungarvan Limited i CH p Sligo Stiefel Laboratories Ireland Limited i Ph p Romania Brasov Europharm Holding S. A. Ph, CH s Bucharest GlaxoSmithKline GSK S. R. L. Ph d m s Russian Moscow GlaxoSmithKline Trading ZAO Ph e m Federation Spain Madrid GlaxoSmithKline S. A. Ph m Switzerland Muenchenbuchsee GlaxoSmithKline AG Ph m USA USA Research Triangle Park Stiefel Laboratories, Inc. Ph m p Marietta Corixa Corporation Ph p r Philadelphia GlaxoSmithKline LLC Ph, CH d e m p r s Pittsburgh GlaxoSmithKline Consumer Healthcare, L. P. CH m p 88 Pittsburgh Block Drug Company, Inc. CH m Wilmington GlaxoSmithKline Holdings Americas Inc. Ph, CH h Wilmington GlaxoSmithKline Capital Inc. Ph, CH f Research Triangle Park ViiV Healthcare Company Ph m 77 Rockville Human Genome Sciences, Inc. Ph p r 202 GSK Annual Report 2013 43 Principal Group companies continued Location Subsidiary Sector Activity % Americas Canada Mississauga GlaxoSmithKline Inc. Ph m p Mississauga GlaxoSmithKline Consumer Healthcare Inc. CH m Laval ID Biomedical Corporation of Quebec Ph d e p r Mexico Mexico City GlaxoSmithKline Mexico S. A. fide C. V. Ph, CH e m p s Asia Pacific Australia Boronia GlaxoSmithKline Australia Pty Ltd Ph, CH d e m p r China Beijing GlaxoSmithKline China Investment Co. Ltd Ph, CH d h m r s Hong Kong GlaxoSmithKline Limited Ph, CH m Tianjin Sino-American Tianjin Smith Kline & French Laboratories Ltd CH e m p 55 India Mumbai GlaxoSmithKline Pharmaceuticals Limited Ph m p 51 Gurgaon GlaxoSmithKline Consumer Healthcare Limited CH d e m p r s 72 Malaysia Selangor GlaxoSmithKline Consumer Healthcare Sdn Bhd CH m Pakistan Karachi GlaxoSmithKline Pakistan Limited Ph, CH e m p r 83 Philippines Makati GlaxoSmithKline Philippines Inc Ph, CH d e m Singapore Singapore Glaxo Wellcome Manufacturing Pte Ltd Ph d e p r s Singapore GlaxoSmithKline Pte Ltd Ph, CH d e m s South Korea Seoul GlaxoSmithKline Korea Limited Ph, CH m r Thailand Bangkok GlaxoSmithKline Thailand Limited Ph, CH m Japan Japan Tokyo GlaxoSmithKline K. K. Ph, CH d m p Latin America Argentina Buenos Aires GlaxoSmithKline Argentina S. A. Ph, CH e m p r Brazil Rio fide Janeiro GlaxoSmithKline Brasil Limitada Ph, CH d e m p Colombia Bogota GlaxoSmithKline Colombia S. A. Ph, CH m Venezuela Caracas GlaxoSmithKline Venezuela, C. A. Ph, CH m Middle East & Africa Egypt Cairo GlaxoSmithKline S. A. E Ph, CH e m p 91 Nigeria Lagos GlaxoSmithKline Consumer Nigeria plc ii Ph, CH e m p 46 South Africa Johannesburg GlaxoSmithKline South Africa Pty Limited Ph, CH d e m p Turkey Istanbul GlaxoSmithKline Ilaclari Sanayi five Ticaret A. S. Ph, CH e m p Associate Sector Activity % Middle East & Africa Location South Africa Johannesburg Aspen Pharmacare Holdings Limited iii Ph, CH m p r 12 i Exempt from the provisions of section 7 of the Companies Amendment Act 1986 Ireland.
ii C onsolidated as a subsidiary in accordance with section 1162 4 a of the Companies Act 2006 on the grounds of dominant influence.
iii Equity accounted on the grounds of significant influence.
Directly held wholly owned subsidiary of GlaxoSmithKline plc.
Key Business sector: Ph Pharmaceuticals, CH Consumer Healthcare Business activity: d development, e exporting, f finance, h holding company, i insurance, m marketing, p production, r research, s service Full details of all Group subsidiaries and associates will be attached to the companys Annual Return to be filed with the UK Registrar of Companies.
Each of GlaxoSmithKline Capital Inc. and GlaxoSmithKline Capital plc is a wholly-owned finance subsidiary of the company, and the company has fully and unconditionally guaranteed the securities issued by each of GlaxoSmithKline Capital Inc. and GlaxoSmithKline Capital plc.
